MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date

Wednesday, June 22, 2016

12:00pm-1:30pm
The effects of gait and balance training on walking economy in early and mid stage Huntington’s disease

J.L. Kubica, J. Szymura, E. Mirek, M. Filip, M. Wiecek, M. Maciejczyk, M. Rudzinska, U. Pustulka-Piwnik, J. Stozek, S. Pasiut (Krakow, Poland)

Huntington's disease  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The efficacy of quantitative 99mTc-TRODAT-1 SPECT in diagnosis of aged patients with Parkinson’s disease

C.F. Lee, C.Y. Wei, G.U. Huang, I.J. Chen, B. Hsu (Changhua, Taiwan)

Parkinson's disease: Neuroimaging and neurophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The evaluation of metabolic differences by using 18F-FDG-PET/CT in demented and non demented Idiophatic Parkinson’s disease patients

S. Altinayar, M. Bakir, Y. Demirtas, Y. Kaplan (Malatya, Turkey)

Cognitive disorders  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The feasibility of measuring fatigability in early-stage Parkinson’s disease using functional MRI

Y. Xing, N. Bajaj, S.T. Schwarz, D.P. Auer (Nottingham, United Kingdom)

Parkinson's disease: Neuroimaging and neurophysiology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The improvement of a tardive diskinesia movements by inline skating

S.C.B. Casagrande, R.G. Cury, A.C.d.L. Pardini, D.B. Coelho, C.d.O. Souza, T.G. de Oliveira, M.G.d.S. Ghilardi, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

Phenomenology and clinical assessment of movement disorders  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The interactive walkway: Towards assessing gait-environment interactions in a clinical setting

D.J. Geerse, M. Roerdink, B. Coolen, J. Marinus, J.J. van Hilten (Leiden, Netherlands)

Phenomenology and clinical assessment of movement disorders  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The International Parkinson and Movement Disorder Society – non-motor rating scale (MDS-NMS): Results from the cognitive pre-testing and phases 1 and 2 of an international validation

K. Ray Chaudhuri, D. Weintraub, A. Schrag, P. Martinez-Martin, On behalf of EUROPAR, The MDS Non-Motor PD Study Group (London, United Kingdom)

Rating scales  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The movement disorder associated with NMDAR-antibody encephalitis: An expert-rater video study

J.A. Varley, K.P. Bhatia, R.C. Dale, V. Fung, T. Granata, M.A.J. Tijssen, A. Lang, J.P. Lin, M. Lim, T. Lynch, N. Nardocci, K.D. Sethi, S.R. Irani (Oxford, United Kingdom)

Clinical Phenomenology and Rating Scales
12:00pm-1:30pm
The nucleocytoplasmic transport of ataxin-3 as pathogenic mechanism in spinocerebellar ataxia type 3

T. Schmidt, A. Sowa, I.M. Martins, M. Abedi, Z. Wang, J. Schmidt, H. Tricoire, O. Riess (Tübingen, Germany)

Ataxiz, Choreas
12:00pm-1:30pm
The patient’s perspective: The effect of dopamine on Parkinson symptoms

H. Zach, M.F. Dirkx, J.W. Pasman, B.R. Bloem, R.C. Helmich (Vienna, Austria)

Parkinson's disease: Neuroimaging and neurophysiology  ·  Exhibit Hall located in Hall B, Level 2
  • «Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 54
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley